AI-generated suggestion. Not a real company. Not a forecast.
Acme Estimated number of RR-TB incident cases Co. (open quest, not a real company)
This placeholder is not counted as supply. It has no revenue, funding, or valuation.
Founder starter pack
A company whose job is Estimated number of RR-TB incident cases, and whose progress report is the sourced figure of 390,000 cases in 2024.
Customer: The people counted in the headline metric, and the payer that already spends money when the condition gets worse.
First product: one measured pilot in one health system. Pick the headline metric, pick one site, and see if that sourced number moves.
Metrics to move
- Estimated number of RR-TB incident cases: 390,000 cases (2024) Source
Key papers
Most-cited OpenAlex articles returned for a short title search on this problem. A neighboring topic can still appear. This is not a curated reading list.
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa · 2006 · 1,727 citations in OpenAlex
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis · 2020 · 1,110 citations in OpenAlex
- WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update · 2011 · 1,099 citations in OpenAlex
- Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis · 2010 · 1,050 citations in OpenAlex
- The Emergence of Drug-Resistant Tuberculosis in New York City · 1993 · 935 citations in OpenAlex
- National Survey of Drug-Resistant Tuberculosis in China · 2012 · 633 citations in OpenAlex
- Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis · 2022 · 628 citations in OpenAlex
- Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli · 2009 · 621 citations in OpenAlex
Datasets
Funders and grant programs
- NIH RePORTER 1 projects matched this search in FY2026. A match is not an open call.
- Wellcome Wellcome lists open research funding. Check the current scheme before applying.
Comparable companies
No comparable company was sourced.